(Edetate disodium + ethyl alcohol + minocycline hydrochloride) is under clinical development by Citius Pharmaceuticals and currently in Phase III for Pseudomonas aeruginosa Infections. According to GlobalData, Phase III drugs for Pseudomonas aeruginosa Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Edetate disodium + ethyl alcohol + minocycline hydrochloride) LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Edetate disodium + ethyl alcohol + minocycline hydrochloride) overview
Mino-Lok is under development for the treatment of unspecified infectious diseases (catheter-related bloodstream infections (CRBSIs)) caused by Staphylococcus epidermidis, Staphylococcus aureus, Candida spp and Pseudomonas aeruginosa. It is administered through intravenous route in the form of solution. The drug candidate consists of minocycline, edetate (disodium EDTA) and ethyl alcohol. It is developed based on the lock solution technology.
Citius Pharmaceuticals overview
Citius Pharmaceuticals (Citius) is a specialty pharmaceutical company that focuses on the development and commercialization of anti-infective products in adjunct cancer care and critical care drug products. The company’s proprietary product candidates include Mino-Lok, an antibiotic lock solution intended for the treatment of patients with catheter-related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine intended to provide anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. Citius is headquartered in Cranford, New Jersey, the US
For a complete picture of (Edetate disodium + ethyl alcohol + minocycline hydrochloride)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
